{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.03","value":"64.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"baseline- global"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.14","value":"90.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"12 months- global"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.2","value":"70.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"baseline- emotion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.36","value":"78.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"12 months- emotion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.98","value":"65.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"baseline- function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.66","value":"84.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"12 months- function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.91","value":"60.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"baseline- physical"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.84","value":"73.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"12 months- physical"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The M.D. Anderson Dysphagia Inventory (MDADI) was used to assess effects of dysphagia on the quality of life of patients with head and neck cancer. It incorporates 3 domains (emotional, functional, and physical) as well as 1 global question. Each subscale with five possible responses scored on a scale of 1 to 5 (strongly agree, agree, no opinion, disagree and strongly disagree). Scores range from 0 (extremely low functioning) to 100 (higher functioning). Higher MDADI score represents better day-to-day functioning and better quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Erlotinib\n\nerlotinib hydrochloride\n\npemetrexed disodium\n\nquality-of-life assessment\n\nintensity-modulated radiation therapy","id":"OG000","title":"Erlotinib"}],"paramType":"MEAN","populationDescription":"Data not collected on all participants at 12 months. Data corresponds to Phase II patients.","reportingStatus":"POSTED","timeFrame":"baseline and 12 months","title":"Change in Quality of Life: MDADI","type":"SECONDARY","unitOfMeasure":"units on a scale"}